Skip to content
FDA Approval: Taletrectinib and ROS1 NSCLC episode artwork

Jun 24, 2025 29 min

FDA Approval: Taletrectinib and ROS1 NSCLC

from Lung Cancer Considered Hosted by IASLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

FDA Approval: Taletrectinib and ROS1 NSCLC

0:00 29:20

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 29 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on June 24, 2025.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.